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Background: Pancreatic cancer is one of the most lethal cancers worldwide. The aim of this study was to
determine the expression pattern, clinical significance, and biological functions of Wnt5a in pancreatic cancer.
Methods: Immunohistochemistry was performed to examine Wnt5a expression in 134 surgically resected
pancreatic adenocarcinoma and adjacent normal pancreatic tissues. Associations of Wnt5a expression with
clinicopathological factors and cancer-specific survival were analyzed. The effects of Wnt5a overexpression or
silencing on the invasiveness and epithelial-to-mesenchymal transition (EMT) of pancreatic cancer cells were
studied. Silencing of β-catenin by small interfering RNA was done to determine its role in the Wnt5a-mediated
tumor phenotype.
Results: The percentage of Wnt5a positive expression showed a bell-shaped pattern in pancreatic cancer tissues,
peaking in well-differentiated carcinomas. The median cancer-specific survival was comparable between patients
with positive versus negative expression of Wnt5a. Overexpression of Wnt5a promoted the migration and invasion
of pancreatic cancer cells, whereas Wnt5a depletion had an inhibitory effect. In an orthotopic pancreatic cancer
mouse model, Wnt5a overexpression resulted in increased invasiveness and metastasis, coupled with induction of
EMT in tumor cells. Treatment with recombinant Wnt5a elevated the nuclear β-catenin level in pancreatic cancer
cells, without altering the Ror2 expression. Targeted reduction of β-catenin antagonized exogenous Wnt5a-induced
EMT and invasiveness in pancreatic cancer cells.
Conclusion: Upregulation of Wnt5a promotes EMT and metastasis in pancreatic cancer models, which involves
activation of β-catenin-dependent canonical Wnt signaling. These findings warrant further investigation of the
clinical relevance of Wnt5 upregulation in pancreatic cancer.
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Pancreatic cancer is a malignant tumor of the pancreas,
with an estimated 277,000 new cases and 266,000 deaths
annually worldwide [1]. Pancreatic cancer has an ex-
tremely poor prognosis. The 5-year survival rate of pa-
tients with pancreatic cancer is only about 4% [2].
Currently, surgical resection remains the only potentially
curative treatment for localized tumors that are confined
to the pancreas. Unfortunately, 80-85% of patients present* Correspondence: mhzhu07@126.com
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reproduction in any medium, provided the orwith advanced unresectable disease at initial diagnosis [3].
Moreover, pancreatic cancer usually exhibits a poor re-
sponse to most chemotherapeutic agents. Therefore, there
is an urgent need to uncover the biological mechanisms
contributing to development and progression of pan-
creatic cancer.
The lethal nature of pancreatic cancer is largely attribut-
able to its propensity for early lymphatic invasion and dis-
tant metastasis. In general, metastasis involves a series of
events, including loss of cell-cell adhesion, increased mo-
tility/migration, intravasation into blood and/or lymph
vessels, disseminating through the circulation, extravasa-
tion, and colonization at distant sites [4]. AccumulatingThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tion (EMT) plays an important role in tumor progression
and metastasis in various solid tumors including pancre-
atic cancer [5,6]. During EMT epithelial cells undergo
morphological changes and convert to a mesenchymal cell
phenotype. Also, there are characteristic alterations in
molecular markers, i.e., downregulation of epithelial adhe-
sion molecule E-cadherin and upregulation of mesenchy-
mal markers, such as vimentin and N-cadherin. Induction
of EMT in pancreatic cancer cells is associated with in-
creased migratory capacity and invasiveness [7,8].
Wnt proteins constitute a large family of secreted lipid-
modified glycoproteins. The Wnt family is implicated in a
variety of cellular processes, such as proliferation, apop-
tosis, differentiation, and migration [9]. Each family mem-
ber exhibits unique expression patterns and distinct
biological functions. Wnt signaling can be broadly divided
into two categories: the canonical, β-catenin-dependent
pathway and the non-canonical β-catenin-independent
pathway [10]. Wnt5a has been identified as a non-
canonical Wnt protein. Many studies have documented a
crucial role for Wnt5a in cancer progression and metasta-
sis, contributing to cancer cell migration and invasion
[11,12]. Antibody-mediated suppression of Wnt5a activity
results in the prevention of metastasis of gastric cancer
cells [13]. However, conflicting results are obtained in dif-
ferent cellular contexts. Hansen et al. [14] reported that
Wnt-5a can inhibit breast cancer cell migration in a
CREB-dependent manner.
It has been documented that Wnt5a is upregulated
during pancreatic carcinogenesis and mediates the mi-
gration and invasion of pancreatic cancer cells induced
by the transcription factor CUTL1 [15]. The aim of this
study was to determine the expression pattern and clin-
ical significance of Wnt5a in pancreatic cancer and clar-




A total of 134 human pancreatic adenocarcinoma and ad-
jacent normal pancreatic tissues were obtained from the
Changhai Hospital Affiliated to Second Military Medical
University (Shanghai, China), which were resected at this
hospital between January 2002 and December 2004.
Demographic and clinicopathological data of patients
were collected from impatient medical records. Follow-up
data were available in 45 patients of this cohort (34%).
The median follow-up period was 15 months (range, 4–
60 months). Tumor histological differentiation was de-
fined by two pathologists, according to the World Health
Organization classification [16]. In total, 30 cases were
well differentiated, 83 moderately differentiated, and 21
poorly differentiated. Written informed consent wasobtained from all patients and this study was approved
by the Ethical Committee of Changhai Hospital of the
Second Military Medical University.
Cell culture and transfection
Human pancreatic cancer cell lines PANC-1 and BXPC-
3 were obtained from Institute of Cellular Research,
Chinese Academy of Science, Shanghai, China, and cul-
tured in RPMI 1640 medium supplemented with 10% fetal
bovine serum (FBS), 100 U/mL penicillin and 100 U/mL
streptomycin (all from Invitrogen-Gibco, Carlsbad, CA,
USA) in a 5% CO2 incubator at 37°C.
Wnt5a-expressing plasmid was constructed by sub-
cloning the human Wnt5a cDNA into the pcDNA3.1
vector (Invitrogen, Carlsbad, CA, USA). Knockdown of
endogenous Wnt5a expression in pancreatic cancer
cells was achieved using small interfering RNA (siRNA)
technology. The target sequence was 5'-GTTTTGGCC
ACTGACTGA-3'. The Wnt5a siRNA expression cassette
was subcloned into the expression vector pcDAN6.2. Cell
transfection was performed using the Lipofectamine 2000
Transfection Reagent, according to the manufacturer’s in-
struction (Invitrogen). To establish stable clones, trans-
fected cells were selected with G418 (Invitrogen-Gibco)
or blasticidin (Merck, Darmstadt, Germany). After selec-
tion for 2–3 weeks, single colonies were isolated and
screened for Wnt5a expression by Western blot analysis.
β-Catenin and scrambled control siRNAs were pur-
chased from GenePharma company (Shanghai, China).
For assessment of the role of β-catenin in Wnt5a-
mediated tumor phenotype, pancreatic cancer cells were
transfected with β-catenin or control siRNA (20 nM) 24
h before the addition of recombinant human Wnt5a
(200 ng; Abcam, Cambridge, MA, USA). After incuba-
tion for another 24 h, cells were tested for evidence of
EMT and invasion ability.
Western blot analysis
Cells were lysed with the lysis buffer containing a protease
inhibitor mixture (Roche Applied Science, Mannheim,
Germany) on ice for 30 min. Cytoplasmic and nuclear
proteins were separately isolated using the Proteo JET
Cytoplasmic and Nuclear Protein Extraction Kit, ac-
cording to the manufacturer’s instructions (Fermentas,
Burlington, ON, Canada). For dephosphorylation of Ror2
receptor, lysates were treated with 20 unit of calf intestinal
alkaline phosphatase (CIAP; Promega, Madison, WI, USA)
at 37°C for 1 h. Proteins were separated with 10% sodium
dodecyl sulfate polyacrylamide gels and transferred onto
polyvinylidene difluoride membranes (Bio-Rad, Hercules,
CA, USA). The membranes were probed with specific
antibodies and reactive proteins were detected using
ECL chemiluminescence (Amersham Pharmacia
Biotech, Piscataway, NJ, USA). Sources of antibodies
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(Abcam, Cambridge, MA, USA; 1:1000), anti-E-cadherin
(Abcam; 1:1000), anti-vimentin (Abcam; 1:2000), anti-
phosphorylated Ror2 (Abgent, San Diego, CA, USA;
1:500), anti-snail (Abcam; 1:100), anti-β-catenin (Abcam;
1:1000), anti-glyceraldehyde-3-phosphate dehydrogenase
(GAPDH; Kangchen, Shanghai, China; 1:3000), and anti-
lamin A/C (sc-20681, Santa Cruz Biotech, Santa Cruz,
CA, USA; 1:1000). The intensity of each band was mea-
sured by densitometric analysis using the Quantity One
software (Bio-Rad).
Immunohistochemistry
Examination of the expression and distribution of
Wnt5a in pancreatic cancer tissues was performed using
the streptavidin-peroxidase-biotin immunohistochemical
method. In brief, 4-μm paraffin-embedded sections were
deparaffinized and rehydrated. Endogenous peroxidase ac-
tivity was blocked by 3% hydrogen peroxide for 15 min.
After antigen retrieval, sections were incubated with 5%
serum to avoid the non-specific binding. The primary
antibodies against Wnt5a, vimentin, and E-cadherin, each
diluted in 1:50, were added onto the sections and incu-
bated at 4°C overnight. The sections were then treated
with biotinylated secondary antibodies, followed by incu-
bation with streptavidin-horseradish peroxidase complex
(Santa Cruz Biotech). Immunoreactivity was visualized with
diaminobenzidine (Sigma-Aldrich, St. Louis, MO, USA).
The sections were counterstained with hematoxylin. For
blank controls, the primary antibody was omitted. For
negative controls, the primary antibody was replaced by
nonimmune serum.
The stained slides were scored independently by two pa-
thologists blinded to clinical data. The proportion of posi-
tive tumor cells was scored as follows: 0 (≤10% positive
tumor cells); 1 (11-24% positive tumor cells); 2 (25-50%
positive tumor cells); 3 (51-75% positive tumor cells), and
4 (>75% positive tumor cells). Staining intensity was
graded according to the following criteria: 1 (absent or
weak staining); 2 (moderate staining) and 3 (strong stain-
ing). Staining index (SI) was calculated as the product of
the proportion of positive tumor cells and staining inten-
sity score. The cut-off value for distinguishing positive
and negative Wnt5a expression was set as an SI of 3.
Cell migration assay
Transfected PANC-1 and BXPC-3 cells were seeded onto
fibronectin-coated 6-well plates in RPMI 1640 medium
with 0.5% FBS. After 24 h, the cells were scratched using
a sterile pipette tip, washed twice, and incubated in
serum-free medium. The extent of scratch closure was
quantified by measuring the area of the scratch before
and 24 h after migration and results were expressed as
percentage of wound closure.Transwell invasion assay
The Matrigel was diluted in 1:3 with ice-cold serum-free
medium, added on the filters, and dried under a hood.
RPMI 1640 medium with 10% FBS was applied to the
lower chamber. Cells (2 × 105) suspended in serum-free
medium were seeded into the upper chamber and incu-
bated at 37°C for 24 h. The cells on the upper surface of
the filter were removed by wiping with a cotton swab.
The filters were fixed and stained with crystal violet. The
cells that penetrated to the lower surface of the filter
were counted.
Orthotopic pancreatic tumor model
Four-week-old nude mice (Crl:NU/NU-nuBR) weighing
14 to 16 g were obtained from Shanghai Laboratory Ani-
mal Center of Chinese Academy of Sciences (Shanghai,
China). The animals were housed in a specific pathogen-
free environment with a constant temperature of 25°C in
12-h light/12-h dark cycles and fed with a standard pel-
let diet and water ad libitium. All experiments involving
animals in this study were conducted in accordance with
the Guidelines for the Care and Use of Laboratory Ani-
mals of China. The protocol was approved by the Ani-
mal Care and Use Committee of Chinese Academy of
Sciences (Permit number: No: Lacp0010).
Nude mice were anesthetized by peritoneal injection
of chloral hydrate at 0.4 mg/g body weight. The abdo-
men of animals was opened via a 1-cm longitudinal in-
cision in the left hypochondrium, and the pancreas was
gently exteriorized. A total of 5 ×107 cells per each cell
line were injected into the pancreatic parenchyma nearby
the hilum of the spleen. Afterwards the pancreas was relo-
cated into the abdominal cavity. The abdomen was then
closed with 6–0 absorbable vicryl sutures. Each group
consisted of 3 animals. When the orthotopic tumors
reached a size of 1 to 2 cm in the largest diameter, the
mice were humanely killed by cervical dislocation. Organs
with metastatic lesions were photographed. Xenograft tu-
mors were resected, fixed in formalin, embedded in paraf-
fin, and cut into sections. The sections were stained with
hematoxylin and eosin (H&E) or immunostained with ei-
ther anti-vimentin or anti-E-cadherin antibodies, as de-
scribed above.
Statistical analysis
The Chi-square test was performed to examine the asso-
ciations of Wnt5a expression with clinicopathological
factors. The end point of this study was cancer-specific
death. Survival curves were generated using the Kaplan-
Meier method and compared using the log-rank test.
Differences in the means were determined using the Stu-
dent t-test or one-way analysis of variance (ANOVA)
followed by the Tukey test. A P value of <0.05 was con-
sidered statistically significant.
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Wnt5a expression in human pancreatic cancer tissues
Overall, 81.3% (109/134) of all pancreatic cancers showed
positive expression of Wnt5a. The Wnt5a immunostain-
ing intensity increased with the degree of tumoral diffe-
rentiation (Figure 1a-c). In well-differentiated carcinomas,
strong immunostaining for Wnt5a was detected at the
glandular luminal border, whereas in poorly differentiated
carcinomas the immunoreactivity was markedly reduced.
The positive expression rate of Wnt5a was 96.7% (29/30),
85.5% (70/83), and 42.9% (10/21) in well-, moderately-, and
poorly-differentiated carcinomas, respectively (Figure 1d).
In contrast, only 16.4% (22/134) of all adjacent nor-
mal tissues displayed positive staining for Wnt5a.
Taken together, the Wnt5a protein expression ex-
hibited a bell-shaped pattern in human pancreatic
cancer tissues.
Associations of Wnt5a expression with clinicopathological
features and prognosis
The associations of Wnt5a expression with clinicopatho-
logical characteristics are summarized in Table 1. Wnt5a
expression tended to be negatively associated with tumor
histological grade (P < 0.001). However, no statistically
significant relationships were found between Wnt5a ex-
pression and other clinicopathological factors, includingFigure 1 Immunohistochemical analysis of Wnt5a expression in panc
immunostaining of Wnt5a in well-differentiated (a), moderately-differentiat
(d) Determination of the Wnt5a positive expression rate in adjacent norma
pancreatic cancers.gender, age, tumor location, tumor size, perineural inva-
sion, pT classification, and lymph node metastasis.
The prognostic significance of Wnt5a expression in
pancreatic cancer was evaluated using the Kaplan-Meier
survival curve analysis (Figure 2). The patients with
Wnt5a-positive tumors had a slightly higher median
cancer-specific survival than those with negative Wnt5a
expression (8.7 vs. 6.8 months); however, the difference
was not statistically significant (P > 0.05).
Wnt5a increases pancreatic cancer cells migration and
invasiveness in vitro culture
Next, we examined the biological functions of Wnt5a
in pancreatic cancer. The scratch assay revealed that the
percentage of wound closure at 24 h was significantly
(P < 0.05) higher in Wnt5a-overexpressing pancreatic can-
cer cells than in empty vector-transfected cells (Figure 3).
Moreover, siRNA-mediated silencing of Wnt5a pro-
foundly reduced the migration of BXPC-3 cells, but did
not affect the migration of PANC-1 cells (Figure 3).
Transwell invasion assay indicated that Wnt5a overex-
pression significantly (P < 0.05) promoted the invasiveness
of PANC-1 and BXPC-3 cells by 40% and 28%, respectively
(Figure 4). Wnt5a-depleted PANC-1 cells had a signifi-
cantly (P < 0.05) lower invasive capacity than control
siRNA-transfected counterparts (Figure 4). However,reatic cancer and adjacent normal tissues. (a-c) Representative
ed (b), and poorly-differentiated (c) pancreatic carcinomas.
l pancreatic tissues and well-, moderately-, and poorly-differentiated
Table 1 Associations of Wnt5a expression with
clinicopathological characteristics in pancreatic cancer





Age(yr) ≤60 70 16 54 0.192
>60 64 9 55
Gender Male 85 18 67 0.324
Female 49 7 42
Tumor locationb Head 104 19 85 0.768
Body/tail 29 6 23
Tumor size (cm)c ≤2.0 25 3 22 0.559
>2.0 93 18 75
Histological
grade
G1 30 1 29 <0.001a
G2 83 13 70
G3 21 11 10
Perineural
invasion
Absent 25 7 18 0.252
Present 109 18 91
pTc T1 25 3 22 0.319
T2 31 7 24
T3 54 8 46
T4 8 3 5
Lymph node
metastasisd
Absent 24 7 17 0.147
Present 83 13 70
a P < 0.05 indicating significant differences.
b Excluding 1 cases with unknown location of tumor.
c Excluding 16 cases with unknown tumor size and pT classification.
d Excluding 27 cases with unknown lymph node metastasis status.
Figure 2 Kaplan–Meier survival curves in pancreatic cancer patients w
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tential between Wnt5a-deficient and control BXPC-3
cells (P > 0.05).
Wnt5a increases pancreatic cancer invasion and
metastasis in vivo
Using an orthotopic mouse model of pancreatic
cancer, we further assessed the effect of Wnt5a on
pancreatic cancer invasion and metastasis in vivo. Wnt5a-
overexpressing PANC-1 and BXPC-3 cells orthotopically
injected into nude mice showed vascular, lymphatic, and
perineural invasion, as determined by pathological exa-
mination (Figure 5a-c). Moreover, such cells formed
metastatic tumors in multiple sites in all recipient
mice, including the liver (Figure 5d) and mesentery
(Figure 5e). Regarding the empty vector-transfected
cells, no metastasis was found when they were inocu-
lated into nude mice (Figure 5f ).
Wnt5a induces EMT in pancreatic cancer cells
We next checked the effect of Wnt5a on the EMT of
pancreatic cancer cells. Immunohistological analysis
demonstrated that Wnt5a-overexpressing tumors exhib-
ited increased expression of vimentin and decreased ex-
pression of E-cadherin, indicative of the occurrence of
EMT, compared to control tumors derived from empty
vector-transfected pancreatic cancer cells (Figure 6a).
The induction of EMT was further confirmed in pan-
creatic cancer cells transfected with Wnt5a-expressing
plasmids. As shown in Figure 6b, overexpression of
Wnt5a induced a mesenchymal spindle-like morph-
ology in PANC-1 cells under a phase-contrast micro-
scope. Western blot analysis further confirmed that
Wnt5a-overexpressing pancreatic cancer cells undergo anith and without Wnt5a expression.
Figure 3 Effect of Wnt5a on the migration of pancreatic cancer cells. PANC-1 and BXPC-3 cells transfected with indicated plasmids were
wounded and assessed for wound closure after 24 h. Representative images (top panels) of three independent experiments with similar results
are shown. The bar graphs (bottom panels) depict the quantification of cell migration. Results are expressed as mean ± SD.
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Figure 4 Effect of Wnt5a on the invasiveness of PANC-1 and BXPC-3 cells transfected with indicated plasmids. Transwell invasion assay
was performed as described in Methods. Representative images of three independent experiments are shown in top panels. The bar graphs
(bottom panels) show the average number of invaded cells per microscopic field (×200) for each condition.
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vimentin and snail and a concomitant reduction in the E-
cadherin expression (Figure 6c).
Wnt5a activates β-catenin signaling in pancreatic
cancer cells
Western blot analysis revealed that exposure to recom-
binant Wnt5a raised the nuclear level of β-catenin with-
out altering the total level of the protein, in both PANC-1
and BXPC-3 cells (Figure 7a), indicating a translocation of
β-catenin from the cytoplasm to the nucleus. In contrast,
Wnt5a treatment had no influence on the expression and
phosphorylation of Ror2 (Figure 7b). Notably, siRNA-
mediated silencing of β-catenin blocked recombinant
Wnt5a-induced acquisition of the mesenchymal pheno-
type in pancreatic cancer cells (Figure 7c). Moreover, de-
pletion of β-catenin reversed the promotion of cell
invasion by exogenous Wnt5a, resulting in about 74% re-
duction in the invasiveness of tumor cells relative to con-
trol siRNA-transfected cells (Figure 7d).
Discussion
Wnt5a has been found to be upregulated in several solid
tumors, such as gastric cancer [17] and skin cancer [18].
Our data confirm the previous finding that there is anelevation in Wnt5a expression in pancreatic cancer tissues
compared to normal pancreatic tissues [15]. Moreover, we
found that Wnt5a expression intensity increased with the
differentiation degree of tumors. Regarding the expression
extensity in pancreatic cancer tissues, Wnt5a showed a
bell-shaped expression pattern with a significant peak in
well-differentiated carcinomas. Such expression pattern
has also described in other human cancers. Kremenevskaja
et al. [19] reported that Wnt5a shows a low to absent
staining in normal thyroid tissues, strong positive staining
in differentiated thyroid carcinomas, but a complete loss
in all anaplastic tumors. Similarly, low to undetectable
levels of Wnt5a are present in hepatocellular carcinoma
(HCC) and normal liver tissues, whereas strong immuno-
staining was seen in chronic hepatitis, cirrhosis, and dys-
plastic liver cells [20]. The bell-shaped expression pattern
suggests that Wnt5a may play a distinct role in different
cellular contexts. Indeed, Wnt5a acts as a stimulator of
metastasis in gastric cancer cells [13], but as a suppressor
in breast cancer cells [14].
Metastasis remains a major cause of morbidity and
mortality in cancer patients. Wnt5a is capable of regu-
lating numerous biological events associated with me-
tastasis. Cai et al. [21] reported that siRNA-mediated
silencing of Wnt5a in breast cancer cells results in
Figure 5 Effects of Wnt5a on invasiveness and metastasis in an orthotopic pancreatic cancer mouse model. Wnt5a-overexpressing or
control pancreatic cancer cells were orthotopically injected into the pancreatic parenchyma of nude mice. Macroscopic and microscopic
examination of metastases was done as described in Methods. Representative images of H&E staining showing vascular (a), lymphatic (b), and
perineural (c) invasion of Wnt5a-overexpressing PANC-1 cells. Scale bar = 50 μm. Macroscopic appearance of the liver (d)
and mesentery (e) showing prominent metastasis in the mice injected with Wnt5a-overexpressing PANC-1 cells. (f) Representative micrograph
showing H&E-stained sections of control tumors from empty vector-transfected PANC-1 cells. Scale bar = 50 μm.
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suppresses breast cancer cell invasion. Wnt5a contributes
to gastric cancer cell dissemination to the liver through up-
regulation of laminin gamma 2 [22]. In agreement with the
report by Ripka et al. [15], our in vitro evidence indicates
that Wnt5a acts as a potent activator of tumor cell mi-
gration and invasion in pancreatic cancer. However, such
stimulating effects were not consistently observed in
both PANC-1 and BXPC-3 cells. The varying conse-
quences of manipulating Wnt5a further reflect the con-
text dependence of Wnt5a function. Using an orthotopicpancreatic cancer model, we demonstrated that Wnt5a-
overexpressing cancer cells formed metastatic tumors at
multiple sites, whereas control cells failed to metastasize.
These results underscore an important role for Wnt5a in
pancreatic cancer invasion and metastasis.
Induction of EMT has been associated with increased
cancer metastasis and aggressive clinical behaviors [23].
We found that compared to adjacent normal tissues,
Wnt5a-overexpressing tumor tissues had elevated expres-
sion of vimentin and reduced expression of E-cadherin,
indicating the presence of EMT. In vitro studies further
Figure 6 Induction of EMT in Wnt5a-overexpressing pancreatic cancer cells. (a) Immunohistochemical analysis of vimentin and E-cadherin,
two EMT markers, in orthotopic pancreatic tumors. Representative immunostaining images showing increased expression of vimentin and
decreased expression of E-cadherin in Wnt5a-overexpressing PANC-1 tumors, compared to control tumors derived from empty vector-transfected
PANC-1 cells. Scale bar = 50 μm. (b) Cell morphology of PANC-1 cells transfected with Wnt5a-overexpressing plasmid or empty vector under a
phase-contrast microscope. Magnification, ×200. (c) Western blot analysis of the expression of indicated EMT markers in mock- and Wnt5a-transfected
PANC-1 and BXPC-3 cells. Representative blots of three independent experiments with similar results are shown. GAPDH was used as an internal control.
N: nuclear fraction; C: cytoplasmic fraction.
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cells by Wnt5a, as evidenced by increased expression of
vimentin and reduced expression of E-cadherin. The tran-
scription factor snail has been identified as a critical
stimulator of EMT. Many studies suggest that snail repre-
sents a converging point of several signaling pathways in-
cluding Wnt signaling, all eventually leading to EMT
[24,25]. Yook et al. [25] reported that snail is implicated
in Wnt-1-induced EMT in MCF-7 cells. Our data demon-
strated that enforced expression of Wnt5a resulted in in-
creased snail protein expression in pancreatic cancer cells,
suggesting an involvement of snail in Wnt5a-induced
EMT of pancreatic cancer cells.
The interactions of Wnt ligands with transmembrane
receptors known as Frizzled (Fzd) and co-receptors initi-
ate the activation of intracellular signaling pathways.
Wnt5a can exert its biological effects through the ca-
nonical or non-canonical Wnt signaling pathway, largelydepending on the availability of specific receptors [26]. It
has been reported that addition of recombinant Wnt5
led to increased nuclear β-catenin in PANC-1 cells as
well as a significant increase in TCF/LEF-dependent re-
porter activity [15], indicative of an activation of the ca-
nonical signaling pathway. Consistent with this study,
our data showed a promotion of β-catenin nuclear trans-
location in both PANC-1 and BXPC-3 cells by exposure
to recombinant Wnt5a. Moreover, we showed that the
protein level Ror2 receptor remained unchanged after
the treatment with recombinant Wnt5a, suggesting no
activation of the non-canonical Wnt signaling pathway.
Mounting evidence indicates a critical role for the β-
catenin signaling in the pathogenesis of pancreatic
cancer [27,28]. Wang et al. [27] documented that expres-
sion of the ataxia-telangiectasia group D complementing
(ATDC) gene increases β-catenin levels in pancreatic can-
cer, consequently facilitating tumor growth and metastasis.
Figure 7 Western blot analysis of the expression of β-catenin and Ror2 in PANC-1 and BXPC-3 cells with indicated treatments. (a)
Treatment of pancreatic cancer cells with recombinant Wnt5a (200 ng) resulted in an increase in the nuclear β-catenin level. Lamin A/C was used
as a nuclear internal control. N: nuclear fraction; C: cytoplasmic fraction. (b) The Ror2 protein level of pancreatic cancer cells remained unchanged
in the presence of recombinant Wnt5a with or without CIAP. GAPDH was used as an internal control. CIAP, calf intestinal alkaline phosphatase.
(c) PANC-1 cells were transfected with β-catenin or control siRNA 24 h before exposure to recombinant Wnt5a. After incubation for another 24 h,
Western blot analysis was performed to examine the protein expression of indicated EMT markers. The bar graph shows the results of
densitometric analysis. (d) Transwell invasion assay was performed to test the invasiveness of PANC-1 cells transfected with β-catenin or control
siRNA 24 h before treatment with recombinant Wnt5a. The bar graph represents the data from three independent experiments.
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mediates galectin-3 silencing-induced suppression of pan-
creatic cancer cell migration and invasion. Activation of the
β-catenin signaling is linked to initiation of EMT during
pancreatic cancer [29]. In agreement with these findings,
our in vitro data demonstrated that targeting β-catenin
antagonized Wnt5a-induced EMT and invasiveness, in-
dicating an essential role for the β-catenin signaling in
Wnt5a-mediated tumor aggressiveness.
Although the in vitro evidence indicated a master role
of Wnt5a in inducing aggressive tumor phenotypes, the
prognostic impact of Wnt5a expression in pancreatic
cancer appears not to be of significance. We found that
there was no significant difference in the cancer-specific
survival of patients with Wnt5a positive vs. negative
pancreatic tumors. Such inconsistency between the bio-
logical and clinical findings remains to be further clari-
fied. The possibility can not be excluded that tumoralWnt5 expression may have significant prognostic impli-
cations in a subgroup of pancreatic cancer patients.
Conclusion
In conclusion, our data confirm an upregulation of Wnt5a
in pancreatic cancer, especially well-differentiated car-
cinomas. This Wnt protein plays an important role in
regulating EMT and metastasis in pancreatic cancer
models. Such tumor aggressiveness conferred by Wnt5a is
mediated through activation of β-catenin-dependent ca-
nonical Wnt signaling. However, further studies are cer-
tainly needed to clarify the real clinical value of Wnt5a.
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